KZR Kezar Life Sciences, Inc. Stock Quote

KZR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	1.70%	Shs Outstand	51.91M	Perf Week	-1.72%
Market Cap	415.41M	Forward P/E	-	EPS next Y	-1.23	Insider Trans	0.00%	Shs Float	34.05M	Perf Month	-8.13%
Income	-48.20M	PEG	-	EPS next Q	-0.26	Inst Own	60.50%	Short Float	6.10%	Perf Quarter	66.15%
Sales	-	P/S	-	EPS this Y	48.40%	Inst Trans	0.73%	Short Ratio	8.15	Perf Half Y	49.39%
Book/sh	2.50	P/B	3.44	EPS next Y	-20.60%	ROA	-31.90%	Target Price	14.75	Perf Year	52.85%
Cash/sh	2.67	P/C	3.22	EPS next 5Y	-	ROE	-34.30%	52W Range	4.61 - 9.79	Perf YTD	64.56%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-12.26%	Beta	0.32
Dividend %	-	Quick Ratio	22.40	Sales past 5Y	-	Gross Margin	-	52W Low	86.33%	ATR	0.55
Employees	47	Current Ratio	22.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.04	Volatility	7.31% 5.47%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-12.90%	Profit Margin	-	Rel Volume	4.38	Prev Close	8.67
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	254.96K	Price	8.59
Recom	1.70	SMA20	-0.68%	SMA50	8.36%	SMA200	37.32%	Volume	1,117,651	Change	-0.92%

Jul-16-18

Initiated

William Blair

Outperform

Jul-16-18

Initiated

Wells Fargo

Outperform

$30

Jul-16-18

Initiated

Jefferies

Buy

Oct-15-21 02:12PM	10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins Prosight Capital Insider Monkey
Oct-05-21 04:01PM	Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs Business Wire
Sep-21-21 02:34PM	3 Hot Growth Stocks to Beat the Market Volatility TipRanks
Sep-02-21 07:00AM	Kezar Life Sciences to Participate in Two Upcoming Investor Conferences Business Wire
Aug-23-21 07:01AM	Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis Business Wire +13.21%
Aug-12-21 04:02PM	Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates Business Wire
Jul-26-21 04:52AM	Could The Kezar Life Sciences, Inc. (NASDAQ:KZR) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jul-08-21 07:01AM	Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021 Business Wire
Jun-08-21 07:01AM	Kezar Life Sciences Announces Formation of Clinical Advisory Committee Business Wire
Jun-02-21 07:01AM	Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021 Business Wire
Jun-01-21 04:01PM	Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors Business Wire
May-27-21 07:00AM	Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference Business Wire
May-26-21 04:01PM	Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021 Business Wire
May-12-21 04:01PM	Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates Business Wire
May-10-21 04:01PM	Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work Business Wire -6.79%
Apr-19-21 06:45AM	We're Hopeful That Kezar Life Sciences (NASDAQ:KZR) Will Use Its Cash Wisely Simply Wall St.
Apr-10-21 08:30AM	Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting Business Wire
Feb-25-21 04:01PM	Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference Business Wire
Feb-16-21 12:53AM	What Kind Of Investors Own Most Of Kezar Life Sciences, Inc. (NASDAQ:KZR)? Simply Wall St.
Feb-10-21 04:01PM	Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference Business Wire +13.84%
Jan-07-21 04:02PM	Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference Business Wire
Dec-18-20 03:13AM	Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings Simply Wall St.
Dec-15-20 07:52AM	The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga
Dec-14-20 04:01PM	Kezar Life Sciences Added to the Nasdaq Biotechnology Index Business Wire
10:46AM	Is KZR A Good Stock To Buy Now? Insider Monkey
Nov-12-20 04:05PM	Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences Business Wire
Nov-05-20 04:01PM	Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates Business Wire
08:46AM	Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020 Business Wire
Oct-23-20 07:26AM	The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO Benzinga
07:00AM	Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis Business Wire
Oct-19-20 02:25PM	We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate Simply Wall St.
Oct-15-20 07:00AM	Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences Business Wire
Sep-18-20 07:30AM	The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations Benzinga
Sep-17-20 04:01PM	Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology Business Wire
Sep-10-20 07:00AM	Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology Business Wire
Aug-11-20 08:59AM	What Is The Ownership Structure Like For Kezar Life Sciences, Inc. (NASDAQ:KZR)? Simply Wall St.
08:53AM	Is Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Aug-05-20 04:01PM	Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update Business Wire
Aug-03-20 04:01PM	Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences Business Wire
Jul-29-20 05:17PM	Kezar Life Sciences to Release Second Quarter Financial Results and General Business Updates on August 5, 2020 Business Wire
Jun-23-20 09:16PM	Kezar Life Sciences, Inc. (KZR): Hedge Funds In Wait-and-See Mode Insider Monkey
Jun-16-20 09:36AM	Billionaire Ken Griffin Pulls the Trigger on These 3 Penny Stocks TipRanks +5.24%
Jun-12-20 07:01AM	Trade Alert: The Independent Director Of Kezar Life Sciences, Inc. (NASDAQ:KZR), Franklin Berger, Has Just Spent US$550k Buying 15% More Shares Simply Wall St.
Jun-09-20 04:15PM	Why Kezar Life Sciences Is Down Today Motley Fool -12.14%
11:15AM	Is This Flaming Hot Biotech Stock a Buy? Motley Fool
Jun-08-20 08:48PM	Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants GlobeNewswire -9.01%
06:00AM	Kezar Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-03-20 04:02PM	Kezar Provides Data Update from MISSION Study of KZR-616 GlobeNewswire -8.21%
May-28-20 04:01PM	Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference GlobeNewswire
May-20-20 04:42PM	Kezar Announces Presentations During Upcoming Scientific Conferences GlobeNewswire +7.48%
May-11-20 10:35AM	Why Earnings Season Could Be Great for Kezar Life Sciences (KZR) Zacks
09:52AM	Top Ranked Momentum Stocks to Buy for May 11th Zacks
08:35AM	We're Not Very Worried About Kezar Life Sciences's (NASDAQ:KZR) Cash Burn Rate Simply Wall St.
06:56AM	H.C. Wainwright Sticks to Their Buy Rating for Kezar Life Sciences Inc Investing.com
May-07-20 04:01PM	Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +16.70%
May-04-20 04:01PM	Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer GlobeNewswire +13.16%
Apr-09-20 06:08PM	Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals +9.66%
07:00AM	Kezar Provides Statement Regarding COVID-19 Pandemic GlobeNewswire
Mar-24-20 11:30AM	Is Kezar Life Sciences (KZR) Stock Outpacing Its Medical Peers This Year? Zacks +5.38%
Mar-12-20 04:01PM	Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update GlobeNewswire -13.28%
Feb-26-20 04:01PM	Kezar Life Sciences to Present at Cowen and Companys 40th Annual Healthcare Conference GlobeNewswire
Feb-07-20 08:36AM	Franklin Berger Is The Independent Director of Kezar Life Sciences, Inc. (NASDAQ:KZR) And They Just Spent US$314k On Shares Simply Wall St.
Feb-04-20 05:50PM	Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
12:04PM	Wall Street Recommends Picking Up These Falling Knives GuruFocus.com
Jan-31-20 08:13AM	Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire +10.83%
Dec-19-19 07:00AM	Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors GlobeNewswire +6.27%
Dec-16-19 07:29AM	Hedge Funds Are Selling Kezar Life Sciences, Inc. (KZR) Insider Monkey
Dec-09-19 04:05PM	Kezar Life Sciences Highlights Therapeutic Potential of Protein Secretion Inhibitors at the 61st American Society of Hematology Annual Meeting GlobeNewswire
Nov-27-19 04:05PM	Kezar Life Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-18-19 11:39AM	What Type Of Shareholder Owns Kezar Life Sciences, Inc.'s (NASDAQ:KZR)? Simply Wall St.
Nov-14-19 09:44AM	Kezar Life Sciences to Present at Upcoming Investor Conferences GlobeNewswire
Nov-12-19 07:00AM	Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting GlobeNewswire -11.53%
Nov-08-19 04:13PM	Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616 GlobeNewswire
Nov-06-19 04:05PM	Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire +7.29%
Oct-28-19 04:25PM	Kaskela Law LLC Announces Investigation of Kezar Life Sciences, Inc. (KZR) on Behalf of Investors ACCESSWIRE
Oct-01-19 04:05PM	Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting GlobeNewswire -10.06%
Sep-27-19 02:22PM	Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire -6.42%
Aug-28-19 04:05PM	Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences GlobeNewswire
Aug-21-19 01:38PM	Frazier Management Llc Buys Translate Bio Inc, Kezar Life Sciences Inc GuruFocus.com
Aug-14-19 03:40PM	Its not just Bloom Energy: Half of last years Bay Area IPO stocks are underwater American City Business Journals
Aug-07-19 04:05PM	Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-02-19 09:03PM	Shareholder Rights Law Firm Johnson Fistel Launches Investigations PR Newswire
Jun-14-19 08:47AM	The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga -8.97%
Jun-13-19 04:01PM	Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting GlobeNewswire
Jun-10-19 04:05PM	Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616 GlobeNewswire
May-29-19 07:38AM	The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation Benzinga
May-28-19 07:31PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kezar Life Sciences, Inc. - KZR GlobeNewswire -41.39%
07:00AM	Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting GlobeNewswire
May-25-19 10:08AM	Did Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Buy Up More Shares? Simply Wall St.
May-20-19 04:53PM	Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea American City Business Journals
May-14-19 04:05PM	Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences GlobeNewswire
May-09-19 08:56PM	Here is What Hedge Funds Think About Kezar Life Sciences, Inc. (KZR) Insider Monkey
May-07-19 04:05PM	Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-03-19 08:00AM	Kezar Life Sciences to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
Mar-28-19 04:05PM	Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences GlobeNewswire
Mar-26-19 08:00AM	Kezar Life Sciences Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-06-19 04:05PM	Kezar Life Sciences Announces Initiation of Clinical Study to Test a New Drug Product Formulation of KZR-616 GlobeNewswire
Mar-05-19 08:00AM	Kezar Life Sciences to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Mar-04-19 05:00PM	Kezar Life Sciences Strengthens Management Team, Appoints Celia Economides as Senior Vice President, Strategy and External Affairs GlobeNewswire
Dec-20-18 01:05PM	These 4 Biotech Stocks are Picking Up Speed ACCESSWIRE

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BERGER FRANKLIN M	Director	Sep 22	Option Exercise	5.60	8,896	49,818	810,691	Sep 23 04:26 PM
BERGER FRANKLIN M	Director	Sep 21	Option Exercise	6.77	17,792	120,452	801,795	Sep 23 04:26 PM
Fowler John Franklin	CEO	Dec 31	Option Exercise	0.90	16,000	14,400	359,204	Jan 04 08:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience